Skip to main content

OSR Health, Inc.

corporate_fare Company Profile

OSR Health, Inc.

OSRH·NASDAQ·Industrial Applications And Services·CIK 0001840425

As a global healthcare holding company, the company operates with a presence in South Korea, Switzerland, and an office in the United States. It aims to identify, lead, and support the growth of its subsidiaries and potential subsidiary candidates, which are either existing entities or new companies formed through acquiring or licensing assets from industry or academia. The company focuses on innovative research and seeks to pair teams with pharmaceutical or medical device technologies that have the potential to treat diseases and improve healthcare outcomes, providing them with financial and other resources. It evaluates subsidiary candidate opportunities by understanding target indications to identify new approaches and technologies for improved treatment outcomes. The company collaborates with academic and industry leaders, integrating entrepreneurial scientists with business development and leadership teams. Its leadership team supports subsidiaries in transforming discoveries into commercial products. The company's expertise comes from industry veterans, scientists, capital market, and legal professionals. It operates a hub-and-spoke business model, with a centralized executive team partnering with subsidiary management teams to ensure program and corporate alignment.

OSR Health, Inc. (NASDAQ:OSRH) is a publicly traded company in the Industrial Applications And Services sector. Wiseek monitors OSRH SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • OSR Holdings Discloses Preliminary Talks for SillaJen Stake & Pexa-Vec Licensing
  • OSR Holdings Secures 180-Day Nasdaq Extension, Averting Immediate Delisting
  • OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Initiates Strategic Review
  • OSR Holdings Subsidiary Secures $30M Upfront, $815M Potential in Binding License Deal for Lead Cancer Immunotherapy

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$2.91M
Net Income
-$27.06M
Diluted EPS
-$0.80
Op. Cash Flow
-$4.33M
Gross Profit
$592.9K
Operating Income
-$18.34M
Cash & Equivalents
$1.7M
Total Debt
$2.32M
Debt / Equity
0.02×
Net Margin
-9.31×
Shares Outstanding
26.6M sh
Source: 10-K · filed 2026-03-31 · accession 0001213900-26-037395
$0.4701 +0.00% today
52-week range · as of 2026-07-06 $0.3001 – $1.49
Market cap
$16.41M
Volume
1.2M (1.4× avg)
3-mo avg 820.5K
Live data · 2026-07-19 09:22 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed OSRH - Filings & News (Page 2)

OSRH
Mar 16, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.483183
Real-time Price: $0.4701 info
Change: -$0.013083 (-3%) info
Market Cap: $16.407M info
OSRH
Mar 05, 2026, 9:30 AM EST
Source: Acceswire
Importance Score:
7
Price at Filing: $0.409
Real-time Price: $0.4701 info
Change: +$0.0611 (+15%) info
Market Cap: $16.407M info
OSRH
Jan 27, 2026, 9:26 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.7496
Real-time Price: $0.4701 info
Change: -$0.2795 (-37%) info
Market Cap: $16.407M info
OSRH
Jan 14, 2026, 9:27 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.750
Real-time Price: $0.4701 info
Change: -$0.2799 (-37%) info
Market Cap: $16.407M info